MCK Stock Analysis — McKesson
Sector: Healthcare Distribution
AI Verdict
McKesson trades at a discount to the sector on forward earnings despite above-average growth, and its entrenched supply chain moat makes that growth target credible.
Competitive Moat
McKesson operates as a critical middleman in the U.S. healthcare supply chain, distributing pharmaceuticals and medical supplies to hospitals, pharmacies, and clinics. Its scale, logistics infrastructure, and entrenched relationships with both drug manufacturers and healthcare providers create high switching costs and defend its market position.
Summary
McKesson's forward P/E of 16.7x with 22.4% expected EPS growth puts it on watch as a rare value-growth combo in healthcare.
Where It Stands
The stock is up 9.31% over the past year, trades at 16.7x next year's earnings (below the healthcare sector median of 22x), and has an RSI of 50.9 signaling neutral momentum.
Key Metrics
- RSI: 50.9 — Neutral
- Trailing P/E: 20.5x
- Forward P/E: 16.7x
- PEG Ratio: 0.91
- Earnings Growth: +0.2%
- Revenue Growth: +0.1%
- Market Cap: $92.1B
- Dividend Yield: 0.00%
- 1-Year Return: 9.31%
- 52-Week High: $999.00
- 52-Week Low: $637.00
Analyst Consensus
20 Buy · 3 Hold · 0 Sell (23 analysts)
Bull Case
A forward P/E of 16.7x for 22.4% expected earnings growth is cheap for a company with McKesson's scale-driven moat.
Bear Case
If the P/E reverts to the sector median of 22x, there's upside, but if growth stalls and the multiple compresses to 14x (financials sector level), the stock could lose over 16%.
Catalyst to Watch
Watch for quarterly earnings surprises or major contract wins, as these could validate or undermine the 22.4% EPS growth expectation.